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Case Report
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ABSTRACT
Despite the substantial advances in the management of metastatic melanoma
with the introduction of immune checkpoint inhibitors (ICI), many patients develop
disease progression during treatment with immunotherapy. This has been suggested to
be mediated by several mechanisms that contribute to acquired resistance to ICI, one
of which is acquired beta-2 microgloubulin (B2M) mutation. Talimogene laherparepvec
(TVEC) is a genetically modified oncolytic virus that can enhance antitumor immunity.
Temozolomide (TMZ) is an oral alkylating agent that has been suggested to augment
anti-tumor immune response. The clinical significance of TVEC and TMZ in metastatic
melanoma patients who are refractory to immunotherapy is unknown. We report a
case of a patient with immunotherapy refractory intracranial metastatic melanoma
after initial response to ICI who had acquired B2M mutation. The patient received
TVEC and pembrolizumab followed by TMZ. The patient maintained durable response
of her visceral and intracranial disease for 19 months and ongoing. More research is
essential to delineate whether TVEC or TMZ has efficacy in immunotherapy refractory
metastatic melanoma with acquired B2M mutation.

INTRODUCTION

(PFS) and overall survival (OS) over standard of care,
and are now considered first line therapy. The long-term
follow-up studies in patients with metastatic melanoma
who were treated with ICI have further supported the
durable responses achieved. The 5-year survival data with
combined nivolumab (PD-1 inhibitor) and ipilimumab
(CTLA-4 inhibitor) in the CheckMate 067 study has
shown a median OS of more than 60 months in patients
with metastatic melanoma [2]. Similarly, the 5-year follow
up in the KEYNOTE-001 trial of patients with metastatic
melanoma who were treated with pembrolizumab (PD-1
inhibitor) showed a median OS of 38.6 months in treatmentnaïve patients [3]. Despite the remarkable results observed
in multiple clinical trials, a significant number of patients

The development of immune checkpoint inhibitors
(ICI) has transformed our management of metastatic
malignancies and reshaped the field of oncology.
ICIs are monoclonal antibodies that target checkpoint
receptors present on tumor and immune cells in the tumor
microenvironment. These medications unleash the antitumor immune response by targeting checkpoint receptor
proteins such as programmed death-1 (PD-1), programmed
death ligand-1 (PD-L1) or cytotoxic associated lymphocyte
antigen-4 (CTLA-4), among other receptors [1]. For
metastatic melanoma, ICIs were approved after clinical
trials demonstrated improved progression free survival
www.oncotarget.com
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develop progressive disease during treatment [2, 3]. This has
been suggested to be mediated by acquired resistance in the
tumor microenvironment [4]. Of importance to this report,
mutations in the beta-2-microglobulin (B2M), which is an
essential component of MHC class I antigen presentation,
have been suggested to confer acquired resistance to
PD-1 inhibitors in metastatic melanoma [5]. Talimogene
laherparepvec (TVEC) is a genetically modified oncolytic
virus that has been suggested to restore tumor sensitivity to
ICI and overcome resistance in immunotherapy refractory
melanoma [6, 7]. Temozolomide (TMZ) which is an oral
alkylating agent has demonstrated modest efficacy in the
treatment of melanoma prior to the era of targeted therapy
and ICI [8]. Interestingly, there is evidence of the modulating
effect of TMZ on T-cell subsets which could alter the balance
of the immune system but this has not been well studied
in melanoma [9]. Here, we report a case of a patient who
presented with recurrent metastatic melanoma that initially
responded to ICI but later progressed with identification
of an acquired B2M mutation (loss of function) among
other mutations that were detected. The patient was treated
with TVEC and pembrolizumab followed by TMZ. The
patient had complete durable remission for 19 months and
ongoing. We discuss the possible role of TVEC and TMZ in
immunotherapy resistant metastatic melanoma based on the
available literature regarding their modulating effect of the
immune system.

progressing firm subcutaneous nodules in the back,
right chest wall and bilateral axilla (Figure 1A). Positron
Emission Tomography/Computed Tomography (PET/CT)
with [18F] fluorodeoxyglucose (FDG) PET showed right
apical chest wall osteolytic mass with intrapulmonary
invasion, numerous subcutaneous metastatic nodules
and nodular metastases involving the left breast, right
adrenal gland, retroperitoneal and left perianal areas
(Figure 1B). Brain magnetic resonance imaging (MRI)
showed enhancing lesions in the left posterior parietal
lobe measuring 2.4 × 2.1 × 1.8 cm, right parieto-occipital
measuring 3.0 × 2.7 × 2.3 cm (Figure 2) as well as right
inferior temporal lesion measuring 8 mm (not shown in
the figures). The patient underwent gamma knife radiation
to the metastatic brain lesions. Given disease recurrence
and prior response to combination immune checkpoint
inhibitors, she re-started ipilimumab (3 mg/kg) and
nivolumab (1 mg/kg) intravenously every 4 weeks for 4
cycles. The patient completed combination immunotherapy
and developed grade 3 autoimmune hepatitis which was
treated with glucocorticoids and mycophenolate mofetil.
She subsequently developed new neurological symptoms
presenting with headache and gait imbalance. Brain MRI
showed progression in the right parietal lobe, right posterior
cerebellum and the left posterior parietal lesions. She
underwent resection of the symptomatic right parietal and
right posterior fossa lesions and histopathology confirmed
the diagnosis of metastatic melanoma (Figure 1C). This
was followed by 30 Gy whole brain radiation over a total
of 10 fractions. Repeat NGS analysis of a progressive lung
lesion revealed the continued presence of a NRAS (p.Q61H)
mutation with VAF of 49.6%, and IDH1 mutation (p.R132C)
with VAF of 15.3% along with the interval development of
a loss-of-function frameshift mutation in B2M with VAF
of 14.5% (Figure 3A case report timeline). The presence
of a B2M mutation was concerning for the development of
acquired resistance to immunotherapy. We performed RNA
sequencing which revealed overexpression of NRAS and
tumor immune infiltrate composed of 27% immune cells
in the tumor with T-cells constituting 44% (Figure 3B).
Immunohistochemistry demonstrated PD-L1 expression of
more than 30% in the tumor tissue (Figure 3B).
Talimogene laherparepvec (TVEC) was started with
pembrolizumab off-label due to refractory disease with
visceral, cutaneous and brain metastases. The patient had
good response of the subcutaneous nodules and visceral
metastases but had continued radiographic progression
of a left parietal lobe lesion which was associated
with headache, nausea and vomiting and required left
craniotomy with resection (Figure 2). Pathology of the
brain showed reactive changes, hyalinized vessels, bland
necrosis, and no evidence of malignancy (Figure 1D)
most consistent with pseudoprogression. After discussion
with the patient, she commenced temozolomide (TMZ)
at a dose of 150 mg/m2 daily for 5 days out of a 28day cycle. The patient experienced worsening of pre-

CASE PRESENTATION
A 33-year-old female presented due to stage IV
recurrent metastatic melanoma to the bones, lung, liver and
brain. Her medical history was significant for a diagnosis
of melanoma in 2015 in the left arm (T3b) with ulceration
and Breslow depth of 2.3 mm. She underwent wide local
excision and sentinel lymph node biopsy with 2 positive
axillary lymph nodes. This was followed by axillary lymph
node dissection that showed 0 involved nodes out of 23
total lymph nodes. The patient received high dose adjuvant
interferon for 1 year. Surveillance computed tomography
(CT) showed multiple liver, breast and lung lesions
concerning for metastatic disease 8 months after concluding
interferon therapy. Breast biopsy revealed metastatic
melanoma and next-generation sequencing (NGS) showed
NRAS (p.Q61H) mutation with variant allele fraction
(VAF) of 77.4%, IDH1 (p.R132C) mutation with VAF
of 52.4%, TERT promoter mutation and no alterations in
BRAF, KIT, or B2M. RNA sequencing did not demonstrate
overexpression of NRAS. At that time the patient
commenced combination immunotherapy with ipilimumab
(3 mg/kg) and nivolumab (1 mg/kg) intravenously every
three weeks for 4 cycles. CT showed complete response
and maintenance nivolumab was continued for 2 years
complicated by mild vitiligo on the face during treatment.
Six months after stopping maintenance nivolumab, she
presented with the chief complaint of numerous rapidly
www.oncotarget.com
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existing immune-related vitiligo which manifested by
hypopigmented macules and patches on the face, trunk and
lower extremities after the 3rd cycle of TMZ (Figure 1E).
Repeat PET-CT and brain MRI after 19 months of TMZ
initiation showed no evidence of active disease.

initially to ipilimumab-nivolumab followed by nivolumab
maintenance but later had a recurrence of her disease
and was re-challenged with combination ipilimumabnivolumab. Her visceral and intracranial disease continued
to progress despite combination ICI and next-generation
sequencing (NGS) revealed the presence of B2M mutation
which we believe contributed to the acquired resistance
to ICI [5]. Moreover, immunohistochemistry and RNA
sequencing of the tumor tissue at progression after
treatment with ipilimumab and nivolumab demonstrated
an inflamed tumor tissue and abundance of tumor immune
cell infiltrate (PD-L1 expression > 30% and immune cell
infiltrate of 27% in the tumor, respectively). This however
was associated with refractory disease to ICI. Of interest,
the overexpression of NRAS in melanoma cells has
been demonstrated to be associated with downregulation
of MHC class I which consecutively can impair T-cell
function in the tumor microenvironment and contribute
to resistance to ICI [10–12]. Similarly, B2M mutation
has been shown to interrupt MHC class I expression in
the tumor microenvironment in melanoma and lead to
acquired resistance to ICI [5]. One limitation in our case
study is the inability to perform MHC class I expression
in the tumor tissue due to unavailable detection methods
at our institution. However, the presence of both B2M

DISCUSSION
Despite the unprecedented advances in the treatment
of metastatic melanoma with immune checkpoint
inhibitors (ICI), there is a paucity of therapy options in
patients with relapsed and refractory disease following
progression during treatment with ICI. For example,
the rate of progressive disease after initial response to
ICI is estimated to be 64% at 5 years during treatment
with ipilimumab-nivolumab combination and 79% with
pembrolizumab [2, 3]. The development of progressive
disease after initial response has been suggested
to be mediated by acquired resistance in the tumor
microenvironment [4]. This has created an unmet need
for better understanding of resistance pathways leading to
tumor escape from immune surveillance during treatment
with ICI. Our report highlights an example of a patient who
had a relapse with high burden and rapidly progressive
intracranial and extracranial disease. She responded

Figure 1: Recurrent metastatic melanoma. (A) Firm subcutaneous nodules in the axillary area and lateral chest wall. (B) 18F.

Fluorodeoxyglucose positron emission tomographic scan showing multiple metastatic lesions in the subcutaneous tissue, lung, breast,
adrenal gland, pelvic and perianal area before start of ipilimumab-nivolumab (left). Persistent hypermetabolic metastatic lesions with
increase in size an appearance of new lesions after 3 months of ipilimumab-nivolumab (center). Complete metabolic response one year after
temozolomide (right). (C) Histopathology of metastatic brain lesions showing in the left malignant cells with an epithelioid appearance,
harboring vesicular nuclei, and prominent nucleoli (H&E, 40X). In the right picture immunostain for HMB45 demonstrates strong diffuse
cytoplasmic to paranuclear Golgi staining pattern in the tumor cells (B; 40X). (D) histopathology of another resected brain lesion showing
reactive changes, hyalinized vessels, bland necrosis, and no evidence of malignancy Post TVEC and Pembrolizumab (consistent with
pseudoprogression). (E) Hypo-pigmented macules and patches on the back, anterior chest wall and abdomen.
www.oncotarget.com
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Figure 2: MRI of brain of metastatic lesions showing (A) coronal section demonstrating right parieto-occipital lesion at the start of

ipilimumab-nivolumab (arrow). (B) coronal image showing right parieto-occipital and right cerebellar lesions (white arrows) and left
posterior parietal lesion (blue arrow) after three cycles of ipilimumab-nivolumab. (C) Post-surgical resection of two symptomatic lesionsright parieto-occipital and right cerebellar lesions with persistent left posterior parietal lesion (arrow). (D) Enlarging left posterior parietal
lesion post TVEC and pembrolizumab. (E) Surgical cavity after resection of left posterior parietal lesion and one month after TMZ
treatment. (F) Collapsing surgical cavity of left posterior parietal lesion resection with no evidence of recurrent disease in the brain after
19 months of temozolomide initiation.

Figure 3: Timeline of the case and changes in lymphocyte count during treatment with temozolomide. (A) The timeline

of the case report. (B) Demonstrates the evidence of an inflammatory tumor status at progression after treatment with ICI, to the left of the
panel immunohistochemistry staining demonstrates PD-L1 expression > 30% and to the right RNA sequencing using Tempus xT identified
tumor cell infiltration with immune cells composing 27% of the tumor infiltrate with predominance of T-cell infiltration constituting 44%
of the infiltrate.
www.oncotarget.com
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mutation and NRAS overexpression has been shown
as described previously to downregulate MCH class I
expression which we believe contributed to the acquired
resistance in our patient despite the abundance of immune
cell infiltrate including T-cells (44% of the immune
infiltrate). The patient had complete and durable response
of her visceral metastatic disease after initiating TVEC
and pembrolizumab followed by temozolomide (TMZ).
The response observed after sequential administration
of TVEC and pembrolizumab followed by TMZ raises
several important points including the possible role of
sequential use of TMZ after immunotherapy resistance
due to its immunomodulatory effect and the potential role
of overcoming resistance to ICI with TVEC.

not been studied. However, the notion that TMZ can lead
to a decrease in the number of Treg cells that have been
suggested to contribute to the resistance to ICI points
to a possible synergistic effect with ICI. The previous
concept seems intriguing and has been documented in
the literature when TMZ was used with immunotherapy
including interleukin-2 (IL-2), dendritic cells (DC)
autologous therapy and ICI such as PD-1 and CTLA-4
inhibitors which is summarized in Table 1 [19–23]. The
other mechanism by which TMZ is suggested to lead to
immunomodulation in the tumor microenvironment is
through the modulation of nuclear factor (NF)- kB which
increases MHC class I expression in some tumor cells
such as glioma [24].
Notably, sequential use of TMZ with ipilimumab
in melanoma patients showed improved progression free
survival rates at 6 months compared to ipilimumab alone
which further support the previous notion [20]. Our patient
had exacerbation of vitiligo which was a skin immune
related adverse event (IRAEs), mainly at the sites of prior
TVEC injections, three months after initiation of TMZ and
despite being off ICI. This phenomenon is consistent with
the observation that oncolytic adenovirus with TMZ can
induce autophagy and antitumor immune responses [25].
In a similar report, Swami et al. demonstrated complete
and durable remission with the use of metronomic TMZ
in a patient with metastatic melanoma after refractory
disease to pembrolizumab and the observed response
was associated with the development of vitiligo [21]. In
fact, development of vitiligo has been shown to correlate
with improved response and prognosis in patients with
metastatic melanoma treated with ICI [26]. As such, we
believe that the exacerbation of skin IRAE in our patient
during treatment with TMZ was associated with the
maintained response. This raises a question on whether
TMZ interaction with lymphocyte subsets could have
led to induction of autoimmunity and restoration of antitumor immune response. However, whether TMZ could
overcome B2M mutation resistance requires further
validation. Limitations to the hypothesis of a possible
benefit of TMZ with immunotherapy in the reviewed
studies include the small number of subjects included in
these studies, different dosing and sequence of TMZ with
immunotherapy that were used in investigations reported
in the literature (summarized in Table 1) and lack of
mechanistic insight on the role of Treg cells in the tumor
microenvironment and mechanisms of resistance to ICI in
metastatic melanoma.

Immunotherapy and Temozolomide in
metastatic melanoma
Preclinical and clinical data demonstrated a
modulating effect of TMZ on the immune system leading
to unleashed anti-tumor immune response. Several
mechanisms have been proposed for resistance to ICI
such as the interruption of tumor antigen presentation,
inhibition of effector T-cell trafficking due to genetic
and epigenetic alterations, imbalance between subset of
effector and Treg cells and changes in signaling pathways
mediated by cytokines [13–16]. Of importance, Treg cells
have immunosuppressive effect on anti-tumor immunity
and were found to have a role in the resistance to ICI
leading to inadequate effector T-cell function against
tumor cells [17]. Similarly, the depletion of Tregs have
been suggested to restore effector T-cell function and
lead to reactivation of anti-tumor immunity [17]. Another
important mechanism of resistance in malignant melanoma
involves the acquired mutations in the B2M gene leading
to decreased expression of MHC class I molecules which
are essential in antigen presentation and effective cytotoxic
CD8 T-cell function against tumor cells [5].
TMZ is an oral alkylating agent that has shown
modest efficacy and tolerability in patients with metastatic
melanoma in the era preceding approval of targeted
therapies and ICI [8]. In addition, TMZ has a negative
effect on lymphocytes leading to lymphodepletion and
can affect the number and function of Treg cells [18].
As such, Banissi et al. demonstrated that weight based
low dose metronomic administration of temozolomide
led to reduction in circulating Treg cells in rat glioma
models [9]. Similarly, Ridolfi et al. showed a decrease
in circulating Foxp3+ Treg cells after administration
of daily temozolomide for 7 days which was further
enhanced after the administration of autologous dendritic
cell immunotherapy in patients with metastatic melanoma
but this observation did not reflect improved clinical
outcomes [19]. Whether the reduction of circulatory
Treg cells correlates with a decrease in the number of
Treg cells recruited in the tumor microenvironment has
www.oncotarget.com

TVEC and immunotherapy in metastatic
melanoma
TVEC exerts its effect on injectable cutaneous
melanoma sites and has been approved for unresectable
and metastatic melanoma with small number of visceral
metastases [27]. Also, TVEC has been suggested
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Table 1: Studies of Temozolomide with immunotherapy in metastatic melanoma
Tumor Type
(front line vs later line therapy)

Immunotherapy

Dose of TMZ

Sequence of Treatment

Outcome

References

Metastatic Melanoma
(Front line)

Ipilimumab

200 mg/m2

Induction: Ipi IV 10 mg/kg q3w +
TMZ 200 mg/m2 days 1–4 q3w (4
cycles)

mOS: 24.5 months

Patel SP,
et al. 2017
[20]

Maintenance: Ipi 10 mg/kg q12w +
TMZ days 1-5 started on wk 12 and
thereafter q4w

ORR 31.2%

TMZ administered daily after
progression on pembrolizumab
for 6 weeks on, 2 weeks off until
response*

Patient 1: Complete
remission for 2
years

Metastatic Melanoma
(Later Line)

Pembrolizumab

75 mg/m2

mPFS: 5 months

PFS at 6 months
45%
Swami U,
et al. 2019
[21]

Patient 2: Partial
remission for 2
months followed
by PD
Patient 3: durable
response for 8
months before PD

Metastatic Melanoma
(Later Line)

HD IL-2

75 mg/m2

Patient who did not show response
or progressed to HD IL-2 received
TMZ for 3 weeks

Rate of Complete
or near complete
response 67% (6 of
9 patients)

Fateh S,
et al. 2010
[22]

Metastatic Melanoma
(Front Line)

HD IL-2

75 mg/m2

TMZ daily for three weeks followed
by HD IL-12

No difference of
ORR or durable
response compared
to single use of HD
IL-2

Tarhini AA,
et al. 2008
[23]

Metastatic Melanoma
(Later Line)

Autologous
dendritic cells and
IL-2

75 mg/m2

TMZ for 7-14 days prior to DC
therapy and IL-2**

No improvement in
clinical outcome

Ridolfi,
et al. 2013
[19]

Decreased Treg
cells

Other treatments were administered to some patients including ipilimumab and CMP-001. **some patients in this study received CTLA-4 inhibitors. PD:
progressive disease, TMZ: temozolomide, Ipi: ipilimumab, HD IL-2: High dose interleukin-2, mOS: median overall survival, mPFS: median progression
free survival, ORR: overall response rate, DC: dendritic cell, Treg cells: T- regulatory cells.
*

to overcome resistance to ICI [28]. Despite many
mechanisms of resistance that contribute to failure to
ICI in metastatic melanoma, it is hypothesized that type
I interferon pathway remains intact for many of these
patients such as our patient who had no evidence of loss of
downstream signaling through JAK1/2 gene modifications
[28]. Hence, oncolytic viral injection of cancer cells can
lead to upregulation of cytokines such as type I IFN
which can activate natural killer cells. This can lead to the
killing of target cells despite downregulated MHC class
I expression due to mutations such as the loss of B2M,
leading to restoration of anti-tumor immunity which
could explain the systemic response observed in some
the patients who receive TVEC. The activation of type
I IFN pathway by oncolytic viral injection of malignant
cells can explain the circumventing mechanism by which
TVEC can bypass resistance to ICI and lead to restoration
of anti-tumor immunity [29]. The response observed in
our patient with regression of her cutaneous and visceral
disease despite having acquired resistance to ICI could
have been secondary to the administration of TVEC and
www.oncotarget.com

pembrolizumab. Our patient’s intracranial and extracranial
response to TVEC and pembrolizumab is similar to the
report by Blake et al. [30] but our patient had more durable
response which supports a possible role of adding TMZ in
preventing further development of the metastatic disease.
Of interest, the patient had detectable isocitrate
dehydrogenase (IDH) mutation which has been reported to
be present with a frequency of 6% in malignant melanoma
[31]. Interestingly, IDH mutated cancer cells are sensitive
to TMZ but this has not been illustrated well in the case
of melanoma [32]. The lack of evidence on the role of
IDH mutations in tumurogenesis in metastatic melanoma
and the effect of TMZ on IDH mutated melanoma cells
poses intriguing questions on any possible interactions
and benefit of using TMZ in patients with metastatic
melanoma harboring IDH mutations.
Finally, it is important to highlight the limitation in
our case study because of the inability to perform MHC
class I expression at progression, which we believe was
downregulated due to the presence of B2M mutation
and NRAS overexpression. Moreover, it is difficult to
4841
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conclude that the addition of TMZ had an added benefit to
TVEC and pembrolizumab. However, TMZ has efficacy
in intracranial tumors because of its ability to cross the
blood-brain barrier which could have contributed to the
response observed. In addition, development of vitiligo is
known to be associated with a restored immune response
in ICI treated melanoma patients, and this was observed
in our patient after starting TMZ which we believe
contributed to restoration of anti-tumor immune response.

2019; 30:582–88. https://doi.org/10.1093/annonc/mdz011.
[PubMed]
4. O’Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth
MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer
Treat Rev. 2017; 52:71–81. https://doi.org/10.1016/j.
ctrv.2016.11.007. [PubMed]
5. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H,
Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G,
Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra
R, et al. Mutations Associated with Acquired Resistance to
PD-1 Blockade in Melanoma. N Engl J Med. 2016; 375:819–
29. https://doi.org/10.1056/NEJMoa1604958. [PubMed]

CONCLUSIONS
We report the first case to our knowledge of a
successful administration of TVEC with pembrolizumab
followed by TMZ in a patient with ICI refractory
(intracranial and extracranial) metastatic melanoma with
acquired B2M mutation. This report highlights the need
for further investigation on whether TVEC and TMZ have
a role in immunotherapy refractory metastatic melanoma.
This report should be interpreted with caution as more
preclinical and clinical studies are essential to confirm
whether the presence of acquired B2M mutation can
be broken with the use of TVEC and pembrolizumab
followed by TMZ.

6. Ribas A, Mehmi I, Medina D, Lao C, Kummar S, Amin
A, Deva S, Salama AK, Tueting T, Milhem M, Hoimes
CJ, Daniels G, Shaheen M, et al. Phase Ib/II study of the
combination of SD-101 and pembrolizumab in patients with
advanced melanoma who had progressive disease on or
after prior anti-PD-1 therapy. Ann Oncol. 2018; 29:viii451–
viii452. https://doi.org/10.1093/annonc/mdy289.021.
7. Hu-Lieskovan S, Moon J, Campos D, Grossmann KF,
Sosman JA, Ryan CW, Wu M, Ribas A. Reversing
resistance to PD-1 blockade by combination of talimogene
laherparepvec (T-VEC) with pembrolizumab (pembro) in
advanced melanoma patients following progression on a
prior PD-1 inhibitor: SWOG S1607 (NCT#02965716).
J Clin Oncol. 2018 (Suppl 1); 36:TPS9603. https://doi.
org/10.1200/JCO.2018.36.15_suppl.TPS9603.
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